BioCurex, Inc.(fka BOCX)

[Kag]

It would be difficult to pinpoint the underlying reason why investors sold into the Abbott deal announcement almost a year ago. It is always good investment strategy to take profits when it is available. It is my opinion that the stockprice of BOCX is set to do a little soaring with the successful completion of the first milestone which could be announced at any time. That will be Abbott's successful completion of its feasibility review. That announcement will tell Wall Street that Abbott is going to market a RECAF, blood sample, early detection, cancer screening test with a very high sensitivity on its Architect analyzers. Abbott has worldwide rights to market the test. Abbott also has the rights to sublicense the test (with royalties going to BioCurex) for use on other companies rapid test analyzers. Biocurex is also set to recieve minimum royalties commencing with the year ending December 31, 2007. Investors love biotech's with a revenue stream. This stock has the potential to put big smiles on the faces of its investors. What is lacking right now is the announcement of the completion of the first milestone. kag